ADA Scientific Sessions 2026 Abstract
Efficacy and Safety of Extended-Interval PG-102, a GLP-1/GLP-2 Bispecific Agonist, in Adults with Type 2 Diabetes
Trial in peopleInterventions
Papers by Sang-In Yang
3 results
- ADA Scientific Sessions 2025 Abstract
PG-110, a Novel Bispecific Antibody Targeting ActRII and Myostatin, Enhances Fat-Specific Weight Loss and Improves Bone Health in Combination with GLP-1 Agonist Therapy
Experiments in animalsInterventions